<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881761</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH CART 2-3</org_study_id>
    <nct_id>NCT03881761</nct_id>
  </id_info>
  <brief_title>CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma</brief_title>
  <official_title>Clinical Study of CD19/CD20 Bispecific Nanobody-derived CAR-T Cells in Refractroy/Relasped B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Hualong Biotechnology Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with
      relapsed/refractory B cell lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CART cell therapy has become the treatment of choice for patients with relapsed/ refractory B
      cell lymphoma. Currently, CAR-T cells approved for relapsed/refractory B-cell lymphoma are
      mainly CAR19-T cells. Nearly half of patients who relapse after treatment with CAR19-T cells
      are caused by tumor cell antigen escape. Dual-target CAR-T cells targeting CD19 and CD20 may
      reduce the recurrence rate after treatment. This study was to evaluate the efficacy and
      safety of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell
      lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>transfusion of CD19/CD20 bispecific CAR-T cells 24-72 hours after completion of FC regimen pretreatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of study related adverse events</measure>
    <time_frame>one year</time_frame>
    <description>safety of CAR-T cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>three months</time_frame>
    <description>proportion of patients with complete response and partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival time of CAR-T cells in vivo</measure>
    <time_frame>one year</time_frame>
    <description>from the time of CAR-T cells transfusion to the first time that CAR-T cells could not be measured in vivo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>one year</time_frame>
    <description>the enrollment to the first time that disease progression is detected</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>B-Cell Lymphoma Stage I</condition>
  <condition>Refractory</condition>
  <condition>Relapsed</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAR-T cell group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19/CD20 bispecific CAR-T cells</intervention_name>
    <description>collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  expected lifetime＞3 months

          -  CD19/CD20 positive relapsed/refractory B cell lymphoma

          -  KPS＞70

          -  at least one measurable lesion according to RECIST 1.1

          -  enough function of hear, liver, kidney and bone marrow

          -  no history of severe allergies

          -  no other history of malignancy

          -  no other diseases that conflict with this regimen

          -  no serious mental illness

          -  patient or family member sign informed consent

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Severe infectious or viral disease

          -  Active B or C viral hepatitis

          -  Patients who have used large amounts of glucocorticoids or other immunosuppressive
             agents during the last 4 weeks

          -  participated in other clinical studies in the last 3 months, or have been treated with
             other gene products

          -  Others not appropriate to participate in this study examined by the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongping Song, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongping Song, Dr.</last_name>
    <phone>+86-37165587795</phone>
    <email>songyongping2018@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Quanli Gao, Dr.</last_name>
    <phone>+86-37165587483</phone>
    <email>gaoquanli2015@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Affiliate to Zhengzhou University &amp; Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongping Song, Dr.</last_name>
      <phone>+86-37165587795</phone>
      <email>songyongping2018@126.com</email>
    </contact>
    <investigator>
      <last_name>Quanli Gao, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanli Gao, M.D</last_name>
      <phone>+86-15038171966</phone>
      <email>gaoquanli2015@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lu Han, M.D</last_name>
      <phone>+86-13838583031</phone>
      <email>luhan0377@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

